University Library
  • Login
A gateway to Melbourne's research publications
Minerva Access is the University's Institutional Repository. It aims to collect, preserve, and showcase the intellectual output of staff and students of the University of Melbourne for a global audience.
View Item 
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Centre for Neuroscience
  • Centre for Neuroscience - Research Publications
  • View Item
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Centre for Neuroscience
  • Centre for Neuroscience - Research Publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

    Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF

    Thumbnail
    Citations
    Scopus
    Web of Science
    Altmetric
    261
    182
    Author
    Hankey, GJ; Patel, MR; Stevens, SR; Becker, RC; Breithardt, G; Carolei, A; Diener, H-C; Donnan, GA; Halperin, JL; Mahaffey, KW; ...
    Date
    2012-04-01
    Source Title
    LANCET NEUROLOGY
    Publisher
    ELSEVIER SCIENCE INC
    University of Melbourne Author/s
    Donnan, Geoffrey; Wijeratne, Tissa; Parsons, Mark
    Affiliation
    Florey Department Of Neuroscience And Mental Health
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Hankey, G. J., Patel, M. R., Stevens, S. R., Becker, R. C., Breithardt, G., Carolei, A., Diener, H. -C., Donnan, G. A., Halperin, J. L., Mahaffey, K. W., Mas, J. -L., Massaro, A., Norrving, B., Nessel, C. C., Paolini, J. F., Roine, R. O., Singer, D. E., Wong, L., Califf, R. M. ,... Hacke, W. (2012). Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. LANCET NEUROLOGY, 11 (4), pp.315-322. https://doi.org/10.1016/S1474-4422(12)70042-X.
    Access Status
    This item is currently not available from this repository
    URI
    http://hdl.handle.net/11343/33177
    DOI
    10.1016/S1474-4422(12)70042-X
    Description

    C1 - Journal Articles Refereed

    Abstract
    BACKGROUND: In ROCKET AF, rivaroxaban was non-inferior to adjusted-dose warfarin in preventing stroke or systemic embolism among patients with atrial fibrillation (AF). We aimed to investigate whether the efficacy and safety of rivaroxaban compared with warfarin is consistent among the subgroups of patients with and without previous stroke or transient ischaemic attack (TIA). METHODS: In ROCKET AF, patients with AF who were at increased risk of stroke were randomly assigned (1:1) in a double-blind manner to rivaroxaban 20 mg daily or adjusted dose warfarin (international normalised ratio 2·0-3·0). Patients and investigators were masked to treatment allocation. Between Dec 18, 2006, and June 17, 2009, 14 264 patients from 1178 centres in 45 countries were randomly assigned. The primary endpoint was the composite of stroke or non-CNS systemic embolism. In this substudy we assessed the interaction of the treatment effects of rivaroxaban and warfarin among patients with and without previous stroke or TIA. Efficacy analyses were by intention to treat and safety analyses were done in the on-treatment population. ROCKET AF is registered with ClinicalTrials.gov, number NCT00403767. FINDINGS: 7468 (52%) patients had a previous stroke (n=4907) or TIA (n=2561) and 6796 (48%) had no previous stroke or TIA. The number of events per 100 person-years for the primary endpoint in patients treated with rivaroxaban compared with warfarin was consistent among patients with previous stroke or TIA (2·79% rivaroxaban vs 2·96% warfarin; hazard ratio [HR] 0·94, 95% CI 0·77-1·16) and those without (1·44%vs 1·88%; 0·77, 0·58-1·01; interaction p=0·23). The number of major and non-major clinically relevant bleeding events per 100 person-years in patients treated with rivaroxaban compared with warfarin was consistent among patients with previous stroke or TIA (13·31% rivaroxaban vs 13·87% warfarin; HR 0·96, 95% CI 0·87-1·07) and those without (16·69%vs 15·19%; 1·10, 0·99-1·21; interaction p=0·08). INTERPRETATION: There was no evidence that the relative efficacy and safety of rivaroxaban compared with warfarin was different between patients who had a previous stroke or TIA and those who had no previous stroke or TIA. These results support the use of rivaroxaban as an alternative to warfarin for prevention of recurrent as well as initial stroke in patients with AF. FUNDING: Johnson and Johnson Pharmaceutical Research and Development and Bayer HealthCare.
    Keywords
    Clinical Pharmacology and Therapeutics; Cardiology (incl. Cardiovascular Diseases); Expanding Knowledge in the Medical and Health Sciences; Cardiovascular System and Diseases

    Export Reference in RIS Format     

    Endnote

    • Click on "Export Reference in RIS Format" and choose "open with... Endnote".

    Refworks

    • Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References


    Collections
    • Minerva Elements Records [52694]
    • Centre for Neuroscience - Research Publications [91]
    Minerva AccessDepositing Your Work (for University of Melbourne Staff and Students)NewsFAQs

    BrowseCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    My AccountLoginRegister
    StatisticsMost Popular ItemsStatistics by CountryMost Popular Authors